O2 OPTIX (LOTRAFILCON B) AND NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES FOR EXTENDED WEAR

Lenses, Soft Contact, Extended Wear

FDA Premarket Approval P010019 S003

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for 1) a modification to the lotrafilcon a material to market lotrafilcon b contact lenses with an indication for up to 6 nights of extended wear; 2) incorporation of a light blue handling tint, copper phthalocyanine, to both the lotrafilcon a and lotrafilcon b lens materials; and 3) a labeling change for lotrafilcon a lenses to allow for use with enzymatic cleaners. The lotrafilcon b lens will be marketed under the trade name o2 optix (lotrafilcon b) soft contact lenses for extended wear and is indicated for the following: o2 optix (lotrafilcon b) spherical soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1. 50 diopters (d) of astigmatism that does not interfere with visual acuity. O2 optix toric (lotrafilcon b) spherical soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to 6. 00 d or less of astigmatism. O2 optix progressive (lotrafilcon b) spherical soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) and/or presbyopia in phakic or aphakic persons with non-diseased eyes who may require a reading addition of +3. 00 d or less and who may have up to approximately 1. 50 d of astigmatism. O2 optix progressive toric (lotrafilcon b) spherical soft contact lenses are indicated for the optical correction of refractive ametropia (myopia, hyperopia, astigmatism, and presbyopia) in phakic or aphakic persons with non-diseased eyes. The lenses may be worn by persons who have 0. 75 to 2. 75 d of refractive and/or corneal astigmatism. The lenses may be prescribed for daily wear or extended wear for up to 6 nights of continuous wear with removal for disposable, or cleaning and disinfection (chemical, not heat) prior to reinsertion, as recommended by the eye care prof.

DeviceO2 OPTIX (LOTRAFILCON B) AND NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES FOR EXTENDED WEAR
Classification NameLenses, Soft Contact, Extended Wear
Generic NameLenses, Soft Contact, Extended Wear
ApplicantAlcon Laboratories, Inc.
Date Received2004-06-08
Decision Date2004-09-27
PMAP010019
SupplementS003
Product CodeLPM
Advisory CommitteeOphthalmic
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address Alcon Laboratories, Inc. 6201 South Freeway fort Worth, TX 76134-2099

Supplemental Filings

Supplement NumberDateSupplement Type
P010019Original Filing
S083 2022-06-09 30-day Notice
S082
S081 2021-12-17 30-day Notice
S080 2021-08-31 30-day Notice
S079 2021-08-16 30-day Notice
S078 2021-06-04 Normal 180 Day Track No User Fee
S077 2020-11-17 30-day Notice
S076 2020-02-18 30-day Notice
S075 2019-12-23 30-day Notice
S074 2019-11-13 30-day Notice
S073 2019-08-02 30-day Notice
S072
S071 2019-02-21 30-day Notice
S070 2018-11-27 30-day Notice
S069
S068 2018-07-31 30-day Notice
S067 2018-07-13 30-day Notice
S066 2018-06-27 30-day Notice
S065 2018-04-30 30-day Notice
S064 2018-03-22 30-day Notice
S063 2018-02-02 30-day Notice
S062 2017-12-18 Real-time Process
S061 2017-10-17 30-day Notice
S060 2017-09-27 30-day Notice
S059 2017-08-29 30-day Notice
S058 2017-08-28 30-day Notice
S057
S056 2017-08-09 30-day Notice
S055 2017-06-12 30-day Notice
S054 2017-03-24 30-day Notice
S053 2017-01-23 135 Review Track For 30-day Notice
S052 2016-08-12 30-day Notice
S051 2016-06-01 30-day Notice
S050 2016-04-22 Normal 180 Day Track
S049 2016-03-11 30-day Notice
S048 2016-03-01 30-day Notice
S047 2016-02-26 30-day Notice
S046 2016-02-16 30-day Notice
S045 2016-02-09 30-day Notice
S044 2016-01-28 30-day Notice
S043 2015-12-21 30-day Notice
S042 2015-11-12 30-day Notice
S041 2015-09-21 30-day Notice
S040 2015-07-30 30-day Notice
S039 2015-05-01 30-day Notice
S038 2015-04-08 30-day Notice
S037 2015-03-03 30-day Notice
S036 2013-11-12 30-day Notice
S035 2013-08-02 30-day Notice
S034 2012-09-27 30-day Notice
S033 2012-07-10 30-day Notice
S032 2012-05-04 30-day Notice
S031 2012-04-23 30-day Notice
S030 2012-04-16 30-day Notice
S029 2012-02-01 30-day Notice
S028 2011-12-14 Normal 180 Day Track No User Fee
S027 2011-12-12 30-day Notice
S026 2011-09-30 30-day Notice
S025 2011-06-06 Normal 180 Day Track No User Fee
S024 2011-04-21 30-day Notice
S023 2011-04-13 30-day Notice
S022 2011-03-25 135 Review Track For 30-day Notice
S021 2011-03-01 Normal 180 Day Track No User Fee
S020 2011-02-14 30-day Notice
S019 2010-08-09 30-day Notice
S018 2010-08-06 30-day Notice
S017 2010-06-29 30-day Notice
S016
S015 2010-05-05 30-day Notice
S014 2010-03-03 30-day Notice
S013 2010-03-02 30-day Notice
S012
S011 2008-08-25 Normal 180 Day Track No User Fee
S010 2008-07-07 30-day Notice
S009 2008-04-07 Normal 180 Day Track No User Fee
S008 2007-12-17 Real-time Process
S007 2007-09-14 Normal 180 Day Track No User Fee
S006 2007-04-02 Normal 180 Day Track No User Fee
S005 2006-11-20 30-day Notice
S004 2006-08-22 Real-time Process
S003 2004-06-08 Normal 180 Day Track
S002 2003-02-24 Real-time Process
S001 2002-04-05 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.